Skip to content
Linkedin
RLS logo_header
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
Linkedin

First New Subject Dosed in Ph 2 Study of Ampligen and Imfinzi Combination Therapy for Late-Stage Pancreatic Cancer

March 4, 2025

Further development of PD-1xCTLA-4 bispecific antibody vudalimab paused 

March 4, 2025

First Dose Cohort in STARLIGHT-1 Trial Completed and Approval Received to Initiate Higher Dose Cohort

March 4, 2025

1L STK11M NSCLC study discontinued

March 4, 2025

Enrollment starts in Ph 2 Stenoparib trial in Advanced Ovarian Cancer Patients

March 3, 2025

Approval of Protocol Amendment for Ovarian Cancer CER-T Clinical Trial Announced

February 25, 2025

Go-ahead obtained to continue enrolling patients in its pancreatic cancer trial (GOBLET Cohort 5) after a positive safety review

February 25, 2025

Ph 2 opened in High Dose Cohort of INKmune™ Trial in Prostate Cancer

February 19, 2025

Dosing of Cohort A patients in the ACHIEVE Ph 2B trial of TCB008 concluded

February 19, 2025

First Patients Enrolled in FORTIFI-HN01, Ph 2/3 Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

February 17, 2025

Ph 3 waveLINE-010 Trial of Zilovertamab Vedotin for the Treatment of 1L DLBCL Patients initiated

February 11, 2025

First Enrolled Subject in the THANK-u Plus™ Platform-Based Allogeneic CAR-T Trial Achieves sCR at Week 4

February 11, 2025

First Subject Dosed for a Ph 2 Clinical Trial of HLX43

February 11, 2025

Ongoing Ph 2 trial expanded to optimize stenoparib dose and refine DRP® patient selection criteria

February 10, 2025

FIRCE-1 Ph 2 Study of Firi-cel to Discontinue; Advances Remaining Programs While Evaluating Strategic Options

February 4, 2025

Ph 1 SB101 Trial expanded to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas

January 28, 2025

Global Ph 3 Trial of ASP-1929 Photoimmunotherapy in Combination with Pembrolizumab for 1L Recurrent Head and Neck Cancer initiated

January 28, 2025

IDMC recommends continuation of Ph 3 REGAL Trial of GPS in AML

January 28, 2025

First patient dosed with KJ-C2320

January 28, 2025

Patient Enrollment milestone reached for Ph 2 Trial of Ropidoxuridine for Treatment of Patients with GBM

January 28, 2025

Patients Dosed in the First Cohort of the Ph 1/2 SOLARA Trial of BH-30643 for EGFR- and HER2-Mutated NSCLC

January 28, 2025

First Patient Dosed in Ph 2 Study of JNJ-1900 (NBTXR3) for Patients With Stage 3 Unresectable NSCLC

January 28, 2025

First patient dosed in Ph 1 study of IPH4502 in selected advanced solid tumors

January 28, 2025

FDA places clinical hold on ATA3219 CAR-T therapy for the treatment of NHL

January 28, 2025

European Clinical Trial Sites opened and Initial Dosing of Cohort 4 completed for PAS-004 Ph 1 trial

January 21, 2025
Page1 Page2 Page3 Page4 Page5 … Page22

Onco-This-Week

  • Business News
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Conference Coverage

About Us

Sign up for OTW

Linkedin

Disclaimer: The OTW team takes care to share authentic information. In case of any discrepancies please write to newsletter@onco-this-week.com. Our website is an aggregator for open-source oncology news. The information on our website is provided without any representations or warranties. OTW is part of RLS Consultants, a global consulting and training firm focusing exclusively on the healthcare and life sciences industries. RLS is a leading provider of opportunity assessment services, utilizing its comprehensive expertise in strategic market research, forecasting, and modeling, as well as pricing and market access to facilitate commercial assessments. RLS does not have any influence on any news reported on OTW. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of RLS. The content on our website is intended strictly for news and information purposes only and should not be treated as a substitute for medical advice, diagnosis, or treatment. News shared on OTW should not be utilized in real-world analytic products as they are based only on limited and dated open-source information.